Equities analysts expect that Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Rating) will report earnings of ($0.68) per share for the current quarter, according to Zacks. Four analysts have made estimates for Y-mAbs Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.76) and the highest estimate coming in at ($0.61). Y-mAbs Therapeutics posted earnings […]
Y-mAbs Therapeutics, Inc. (NASDAQ:NASDAQ:YMAB) Q1 2022 Results Conference Call May 10, 2022 09:00 AM ET Company Participants Thomas Gad - Founder, Interim CEO and President Bo Kruse - CFO.
Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.
Y-mAbs Therapeutics (NASDAQ:YMAB – Get Rating)‘s stock had its “outperform” rating reissued by investment analysts at Wedbush in a report released on Tuesday, RTT News reports. They currently have a $21.00 price target on the stock, down from their previous price target of $28.00. Wedbush’s price objective would suggest a potential upside of 109.37% from […]